However, the efficacy of JAK3 or JAK1/JAK2 inhibitors can be limited by loss of PTPN6, which augments STAT3 activation in PTCL cells. This evidence concerns the gene JAK2 and mature T-cell and NK-cell non-Hodgkin lymphoma.